Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

ClinicalTrials.gov ID: NCT00024284

Public ClinicalTrials.gov record NCT00024284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study Of Carboplatin And Irinotecan In Patients 1-21 Years Of Age With Refractory Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.

Study identification

NCT ID: NCT00024284
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

carboplatin Drug
irinotecan hydrochloride Drug

Drug

Eligibility (public fields only)

Age range: 1 Year to 21 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2001 (Type not available)
Primary completion: Dec 2003 (Actual)
Completion: Dec 2003 (Actual)
Last update posted: Apr 5, 2013

2001 – 2003

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
Arizona Cancer Center	Tucson	Arizona	85724	—
Children's National Medical Center	Washington D.C.	District of Columbia	20010-2916	—
Washington University Medical Center	St Louis	Missouri	63105	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
St. Jude Children's Research Hospital	Memphis	Tennessee	38105-2794	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00024284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 5, 2013 · Synced Oct 2, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00024284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →